Potential topics selected for 2020 ICER review

ICER has announced its topics of interest for consideration in 2020, including a range of high-profile medicines, some or all of which may lead to full reviews.

The Institute for Clinical and Economic Review (ICER) is an independent US body providing cost-effectiveness analysis for medicines launched in the country. Its reports carry significant influence on payers and their willingness to reimburse drugs.

The potential topics listed in this announcement are:

  • Beta thalassemia: luspatercept (Acceleron Pharma) and lentiviral beta-globin gene transfer (Zynteglo®, bluebird bio)
  • Breast cancer: sacituzumab govitecan (Immunomedics) and trastuzumab deruxtecan (Daiichi Sankyo and AstraZeneca)
  • Cystic fibrosis: VX-445/tezacaftor/ivacaftor (Vertex Pharmaceuticals)
  • Hemophilia A: valoctocogene roxaparvovec (BioMarin Pharmaceutical)
  • High LDL-cholesterol: bempedoic acid (Esperion Therapeutics) and bempedoic acid/ezetimibe (Esperion Therapeutics)
  • HIV and pre-exposure prophylaxis (PrEP): cabotegravir/rilpivirine (ViiV Healthcare) and emtricitabine/tenofovir alafenamide (Descovy®, Gilead Sciences)
  • Lymphoma: lisocabtagene maraleucel (Celgene)
  • Multiple sclerosis: ozanimod (Celgene)
  • Non-alcoholic steatohepatitis (NASH): obeticholic acid (Ocaliva®, Intercept Pharmaceuticals), seladelpar (CymaBay Therapeutics), and cenicriviroc (Allergan)
  • Osteoarthritis-associated pain: tanezumab (Pfizer and Eli Lilly)
  • Postpartum depression: zuranolone (Sage Therapeutics) and brexanolone (Zulresso™, Sage Therapeutics)
  • Rheumatoid arthritis: filgotinib (Gilead Sciences)
  • Sickle cell disease: crizanlizumab (Novartis) and voxelotor (Global Blood Therapeutics)
  • Ulcerative colitis: class review
  • Wet age-related macular degeneration: brolucizumab (Novartis)

ICER says:

“ICER desires to time reports so that they are released as close to FDA approval as possible. Due to the eight-month timespan required to conduct each assessment, some of the drugs under consideration have not yet been submitted to the FDA for approval.”

Read the full announcement here.

Tagged with

Published 11. July 2019 in News